Haisco Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR (HER1; erbB1)-targeting moiety through a linker.
A team of scientists from KTH Royal Institute of Technology and Karolinska Institutet has reported the development and characterization of a new class of small non-immunoglobulin affibody proteins that bind to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA) with high affinity.
Deoxyhypusine synthase (DHPS), which activates the eukaryotic translation initiation factor 5A, shows potential as a therapeutic target against melanoma, which is quite aggressive and prone to metastasize. It is highly expressed in tumors but not in healthy tissues.
ALX Oncology Inc. has developed ALX-2004, an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) with a topoisomerase I inhibitor payload, for treating EGFR+ cancer solid tumors.
Alethio Therapeutics (formerly known as Alethiomics Ltd.) has emerged from stealth with two antibody-drug conjugate (ADC) programs for the treatment of myeloproliferative neoplasms (MPNs).
The U.S. FDA has granted orphan drug designation to Dewpoint Therapeutics Inc.’s DPTX-3186, its first-in-class condensate modulator for the treatment of gastric cancer. The designation follows the recent opening of Dewpoint’s IND application for DPTX-3186 earlier in October, and is the first orphan designation ever granted to a condensate-modulating therapeutic.
Researchers at Zhejiang University and Zhongshan Institute for Drug Discovery have discovered phosphatidylinositol 3-kinase δ (PI3Kδ) and mammalian target of rapamycin (mTOR; FRAP1) dual inhibitors reported to be useful for the treatment of cancer, infections, autoimmune diseases, cardiovascular diseases, inflammatory disorders and neurological conditions.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged dihydrofuro[3,4-f]quinazoline compounds acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) E542K mutant inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
RSS
